Aeterna slips after drug study to diagnose hormone deficiency faces delays

COSCIENS Biopharma

21/03/2022 16:14

** U.S.-listed shares of Canadian biopharma co Aeterna
Zentaris Inc  AEZS.O  fall as much as ~3% to 35 cents 
    ** AEZS expects patient enrollment in late-stage trial of
co's drug for diagnosing childhood-onset growth hormone
deficiency (GHD) to continue late into 2023  urn:newsml:reuters.com:*:nGNXbRPytt 
    ** Co says trial sites originally planned in Ukraine and
Russia are being halted, due to Russia's invasion of Ukraine 
    ** AEZS was planning to recruit at least 25 subjects within
Russia and Ukraine for its late-stage study 
    ** AEZS adds that trial site activation and patient
enrollment continues to be impacted by COVID-19 pandemic
    ** Aeterna's drug, macimorelin, stimulates the secretion of
growth hormone from the pituitary gland, following which hormone
levels are measured for the assessment of GHD
    ** Up to Friday's close, stock up ~1.6% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))